Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SACT-3
- Development stage
- Preclinical
- Lead developer
- Aptorum
- Modality
- Small Molecules
01
Overview
SACT-3 is a repurposed small molecule drug candidate being developed by Aptorum Group Limited. It was identified through Aptorum's proprietary Smart-ACT (Accelerated Commercialization of Therapeutics) platform, which utilizes artificial intelligence and computational screening to identify existing approved drugs for new therapeutic indications, particularly in oncology. SACT-3 is currently in the discovery or preclinical stage and is being investigated for the treatment of various cancers. As a repurposed molecule, SACT-3 benefits from established safety profiles, which may allow for an accelerated clinical development path compared to novel chemical entities.
Beyond the preview
Go deeper on SACT-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SACT-3.